Skip to content
DataLookout
Menu

ROXI-PEAKNCT07697599

Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Study sites: 0 to 1
    • Study completion date: Sep 21, 2029 to Sep 18, 2029
    • Start date changed from estimate of Aug 20, 2026 to Sep 7, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Time-to-first event of centrally adjudicated VTE [symptomatic VTE or incidental VTE or asymptomatic VTE]
Timeframe: Approximately 6 months
Time-to-first event of centrally adjudicated International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
Timeframe: Approximately 6 months

Secondary (18)

Time-to-first event of centrally adjudicated symptomatic VTE [symptomatic Deep Vein Thrombosis (DVT) or symptomatic non-fatal Pulmonary Embolism (PE) or VTE-related death]
Time-to-first event of symptomatic DVT
Time-to-first event of symptomatic non-fatal PE
Time-to-first event of VTE-related death
Time-to-first event of incidental VTE
Show 13 moreShow less
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Time-to-first event of incidental PE (in a segmental or larger pulmonary artery)
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by upper extremity ultrasound)
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Concentrations of REGN7508
Concentrations of REGN9933
Change from baseline in activated Partial Thromboplastin Time (aPTT)
Change from baseline in Prothrombin Time (PT)
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Magnitude of ADA to REGN7508
Occurrence of ADA to REGN9933
Magnitude of ADA to REGN9933

Arms and interventions

REGN7508Experimental
REGN9933Experimental
PlaceboPlacebo comparator

Drugs: REGN7508, REGN9933, Placebo

Sites

1 site in 1 country

  • Arensia Exploratory Medicine at the Research Institute of Clinical MedicineTbilisi, Georgia